https://orcid.org/0000-0001-7884-5466
References
- Sung H , FerlayJ , SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
- Jayaseelan VP , ArumugamP. Exosome-derived ncRNAs as potential drivers of epigenetic reprogramming of cancer stem cells. Epigenomics13(18), 1439–1441 (2021).
- Jayaseelan VP . Emerging role of exosomes as promising diagnostic tool for cancer. Cancer Gene Ther.27(6), 395–398 (2020).
- Zhou K , LiuY , YuanQet al. Next-generation sequencing-based analysis of urine cell-free mtDNA reveals aberrant fragmentation and mutation profile in cancer patients. Clin. Chem.68(4), 561–573 (2022).
- Wei LQ , CheongIH , YangGHet al. The application of high-throughput technologies for the study of microbiome and cancer. Front. Genet.12, 699793 (2021).
- Bi H , FeiQ , LiRet al. Disruption of miRNA sequences by TALENs and CRISPR/Cas9 induces varied lengths of miRNA production. Plant Biotechnol. J.18(7), 1526–1536 (2020).
- Zamecnik PC , StephensonML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad Sci. USA75(1), 280–284 (1978).
- Crooke ST . Vitravene – another piece in the mosaic. Antisense Nucleic Acid. Drug Dev.8(4), vii–viii (1998).
- Sciabola S , XiH , CruzDet al. PFRED: a computational platform for siRNA and antisense oligonucleotides design. PLOS ONE16(1), e0238753 (2021).
- Chan L , YokotaT. Development and clinical applications of antisense oligonucleotide gapmers. Methods Mol. Biol.2176, 21–47 (2020).
- Stahel RA , Zangemeister-WittkeU. Antisense oligonucleotides for cancer therapy – an overview. Lung Cancer41(Suppl. 1), S81–S88 (2003).
- Hagedorn PH , PerssonR , FunderEDet al. Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov. Today23(1), 101–114 (2018).
- Obika S , NanbuD , HariYet al. Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. Tetrahedron Lett.38(50), 8735–8738 (1997).
- Wengel J , VesterB , LundbergLBet al. LNA and α-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids22(5-8), 601–604 (2003).
- Elayadi AN , BraaschDA , CoreyDR. Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry41(31), 9973–9981 (2002).
- Nishikawa M , YanagawaN. Knockdown of nuclear lncRNAs by locked nucleic acid (LNA) gapmers in nephron progenitor cells. Methods Mol. Biol.2161, 29–36 (2020).
- Roberts TC , LangerR , WoodMJA. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov.19(10), 673–694 (2020).
- Sasaki T , HirakawaY , YamairiFet al. Altered biodistribution and hepatic safety profile of a gapmer antisense oligonucleotide bearing guanidine-bridged nucleic acids. Nucleic Acid Ther.32(3), 177–184 (2022).
- Vasquez G , MigawaMT , WanWBet al. Evaluation of phosphorus and non-phosphorus neutral oligonucleotide backbones for enhancing therapeutic index of gapmer antisense oligonucleotides. Nucleic Acid Ther.32(1), 40–50 (2022).
- Yang J , LuoS , ZhangJet al. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease. Neurobiol. Dis.148, 105218 (2021).
- Jayaseelan VP , ArumugamP. Exosome engineering: a promising step toward cancer therapeutics. Epigenomics14(9), 503–506 (2022).
- Yamayoshi A , OyamaS , KishimotoYet al. Development of antibody-oligonucleotide complexes for targeting exosomal MicroRNA. Pharmaceutics12(6), 545 (2020).
- Kamerkar S , LengC , BurenkovaOet al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. Sci. Adv.8(7), eabj7002 (2022).